JACI:日光浴或有益于治疗哮喘

2013-05-21 JACI 生物360

日晒是摄取维生素D的最主要来源。研究显示,身体内维生素D的水平,与哮喘控制有关联。英国专家说,研究显示,哮喘病人多晒太阳,或许有助于治疗。伦敦大学国王学院的一个研究小组说,人身体内维他命D水平过低,与哮喘症状加剧有关联。维他命D主要靠人的皮肤接受太阳光照射产生。最新的研究显示,维他命D对哮喘病人的过分活跃的免疫系统有镇静作用。但是,利用维他命D治疗哮喘病还没有经过临床检验。哮喘病人因呼吸道肿胀变窄

日晒是摄取维生素D的最主要来源。研究显示,身体内维生素D的水平,与哮喘控制有关联。

英国专家说,研究显示,哮喘病人多晒太阳,或许有助于治疗。

伦敦大学国王学院的一个研究小组说,人身体内维他命D水平过低,与哮喘症状加剧有关联。

维他命D主要靠人的皮肤接受太阳光照射产生。

最新的研究显示,维他命D对哮喘病人的过分活跃的免疫系统有镇静作用。

但是,利用维他命D治疗哮喘病还没有经过临床检验。

哮喘病人因呼吸道肿胀变窄而产生呼吸困难。

大多数病人靠激素治疗,但激素类药物不是对所有病人都有效。

阳光维他命

负责研究的哈维洛维茨教授(Prof C Hawrylowicz)说,研究显示,身体内维他命D水平高的人,控制哮喘的能力更强。

研究小组正在进行临床试验,看看晒太阳,即增加阳光维他命,是否能减轻哮喘症状。

哈维洛维茨教授说,人们遮阳或涂抹防晒霜的习惯,可能会增加哮喘的发病率。

但她强调,人们要谨慎对待,因为过多的日晒对身体是有害的。

慈善组织,“英国哮喘”(Asthma UK)的拉赫曼(M Rahman)说,对大多数哮喘病人来说,现有的药物是控制哮喘的有效手段,但它并不是对每一个人都有效,所以探索新的治疗手段是非常重要的。

拉赫曼说,许多人对治疗哮喘的药物可能产生的副作用很担心,如果维他命D被证明可以减少用药量,将对人们的生活质量产生重大影响。


Background
TH17 cells are proposed to play a role in the pathology of asthma, including steroid-resistant (SR) disease. We previously identified a steroid-enhancing function of vitamin D in patients with SR asthma in restoring the impaired response to steroids for production of the anti-inflammatory cytokine IL-10.
Objective
We sought to investigate the production of the TH17-associated cytokines IL-17A and IL-22 in culture in patients with moderate-to-severe asthma defined on the basis of their clinical response to steroids and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25[OH]2D3).
Methods
PBMCs were stimulated in culture with or without dexamethasone and 1,25(OH)2D3. A cytometric bead array, ELISA, and intracellular cytokine staining were used to assess cytokine production. The role of CD39 in inhibition of the TH17 response was studied by using quantitative real-time PCR, flow cytometry, and addition of the antagonist POM-1 to culture.
Results
Asthmatic patients synthesized much higher levels of IL-17A and IL-22 than nonasthmatic control subjects, with patients with SR asthma expressing the highest levels of IL-17A. Glucocorticoids did not inhibit IL-17A cytokine expression in patients and enhanced production in cultures from control subjects. Treatment with 1,25(OH)2D3 with or without dexamethasone significantly reduced both IL-17A and IL-22 levels. An antagonist of the ectonucleotidase CD39 reversed 1,25(OH)2D3-mediated inhibition of the IL-17A response.
Conclusion
Patients with severe asthma exhibit increased levels of TH17 cytokines, which are not inhibited by steroids. 1,25(OH)2D3 inhibits TH17 cytokine production in all patients studied, irrespective of their clinical responsiveness to steroids, identifying novel steroid-enhancing properties of vitamin D in asthmatic patients.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758758, encodeId=7c481e5875867, content=<a href='/topic/show?id=8dfe5919e49' target=_blank style='color:#2F92EE;'>#日光浴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59197, encryptionId=8dfe5919e49, topicName=日光浴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64c537366410, createdName=ms3323097325231039, createdTime=Wed Aug 21 07:41:00 CST 2013, time=2013-08-21, status=1, ipAttribution=)]